NYSE:HIMSHealthcare
A Look At Hims & Hers Health (HIMS) Valuation After Morgan Stanley’s Cautious Growth Commentary
Morgan Stanley’s latest commentary on Hims & Hers Health (HIMS), highlighting slower projected revenue growth and pressure in men’s health, has coincided with high short interest that is drawing fresh attention from both bulls and bears.
See our latest analysis for Hims & Hers Health.
Those concerns have emerged at a time when momentum has cooled, with the share price down 40.42% over 90 days and the 1 year total shareholder return at 2.79%, despite a very large 3 year total shareholder...